Disease · MONDO_0044889
Trials31
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
1 to 20 of 31
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05171647 | A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma | Phase 3 | 208 | 2026-03-06 | Non-Hodgkin Lymphoma | MOSUNETUZUMAB, POLATUZUMAB VEDOTIN | Its record names the disease | ClinicalTrials.gov |
| NCT03484702 | Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 2 | 113 | 2024-12-27 | Lymphoma, Non-Hodgkin | LISOCABTAGENE MARALEUCEL | Its record names the disease | ClinicalTrials.gov |
| NCT04358458 | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas | Phase 1/2 | 46 | 2024-08-13 | Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, High-grade B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma | EPCORITAMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05144009 | A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) | Phase 2 | 41 | 2025-01-30 | Diffuse Large B-cell Lymphoma | LONCASTUXIMAB TESIRINE, RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04836195 | Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma | Phase 1 | 29 | 2025-04-17 | B-cell Non Hodgkin Lymphoma, Advanced Solid Tumor | ZELENIRSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT04313608 | A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma | Phase 1 | 23 | 2024-03-25 | B-cell Lymphoma | GEMCITABINE, GLOFITAMAB, MOSUNETUZUMAB, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT05296525 | Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL | Phase 1/2 | 13 | 2025-03-25 | Non-Hodgkin Lymphoma | NADRAVALEUCEL, RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04933617 | Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas | Phase 1 | 8 | 2024-07-09 | Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Germinal Center B-cell Type (GCB) | COPANLISIB | Its record names the disease | ClinicalTrials.gov |
| NCT03533283 | An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | Phase 1/2 | 211 | Non-Hodgkins Lymphoma | ATEZOLIZUMAB, GLOFITAMAB, OBINUTUZUMAB, POLATUZUMAB VEDOTIN, ZIRCONIUM ZR-89-DESFERRIOXAMINE-IAB22M2C | Its record names the disease | ClinicalTrials.gov | |
| NCT04094311 | Study of Out of Specification for Tisagenlecleucel | Phase 3 | 200 | B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma | TISAGENLECLEUCEL | Its record names the disease | ClinicalTrials.gov | |
| NCT04666168 | A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma | Not applicable | 200 | Non-hodgkin's Lymphoma | CYCLOPHOSPHAMIDE, FLUDARABINE | Its record names the disease | ClinicalTrials.gov | |
| NCT05164770 | Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma | Phase 3 | 160 | High Grade B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, Diffuse Large B Cell Lymphoma, B-cell Non Hodgkin Lymphoma, Mantle Cell Lymphoma | CYCLOPHOSPHAMIDE, DOXORUBICIN, METHOTREXATE, RITUXIMAB, ZANUBRUTINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT04970901 | A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | Phase 1 | 154 | B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma | GLOFITAMAB, LONCASTUXIMAB TESIRINE, MOSUNETUZUMAB, POLATUZUMAB VEDOTIN | Its record names the disease | ClinicalTrials.gov | |
| NCT04329728 | The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies | Phase 1/2 | 144 | Lymphoid Malignancies | DEXAMETHASONE PHOSPHORIC ACID, HYDROCORTISONE | Its record names the disease | ClinicalTrials.gov | |
| NCT06649812 | Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma | Phase 2 | 120 | High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | IBRUTINIB, LENALIDOMIDE, OBINUTUZUMAB, PREDNISONE, VENETOCLAX | Its record names the disease | ClinicalTrials.gov | |
| NCT01742988 | Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma | Phase 1 | 106 | Lymphoma, Relapsed Lymphoma, Refractory Lymphoma, Relapsed and/or Refractory Lymphoma, Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL), Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Double-hit Lymphoma (DHL), Triple-hit Lymphoma (THL), Double-expressor Lymphoma (DEL), High-grade B-cell Lymphoma (HGBL) | FIMEPINOSTAT, RITUXIMAB, VENETOCLAX | Its record names the disease | ClinicalTrials.gov | |
| NCT03620578 | DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL | Phase 2 | 97 | Non Hodgkin Lymphoma, Lymphoma, B-Cell, High-grade B-cell Lymphoma, MYC Translocation, BCL-2 Translocation | CYCLOPHOSPHAMIDE, DOXORUBICIN, ETOPOSIDE, NIVOLUMAB, PREDNISONE, RITUXIMAB, VINCRISTINE | Its record names the disease | ClinicalTrials.gov | |
| NCT04914741 | A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1/2 | 80 | Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | CYCLOPHOSPHAMIDE, DOXORUBICIN, GLOFITAMAB, POLATUZUMAB VEDOTIN, PREDNISOLONE, RITUXIMAB, VINCRISTINE | Its record names the disease | ClinicalTrials.gov | |
| NCT05050630 | Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL | Phase 2 | 73 | Age Range ≥16 Years, Gender Unlimited, Histopathology Confirmed Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma, Received Prior First-line Chemotherapy for DLBCL or HGBL, Failed to Reach CR for Four Cycles, or Relapsed, At Least One Positive Lesion According to the 2014 Lugano Criteria for Hodgkin's and Non-Hodgkin's Lymphoma, ECOG Physical Status Score is 0-3, The Researchers Judged That Life Expectancy Was at Least Three Months, Understand and Voluntarily Sign Written Informed Consent | CARBOPLATIN, ETOPOSIDE, IFOSFAMIDE, LENALIDOMIDE, RITUXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT06271057 | Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse | Phase 2 | 65 | Diffuse Large B-cell Lymphoma Refractory, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory High Grade B-Cell Lymphoma | GOLCADOMIDE | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0044889/trials